Betoptic
Betoptic is a cardioselective beta-1 adrenergic receptor inhibitor in ophthalmic solution or suspension form. It is used to lower internal pressure in the eyes of people with open-angle glaucoma or ocular hypertension. By reducing the production of fluid within the eye, it helps prevent damage to the optic nerve and subsequent vision loss.
Dosage by Body Weight
The usual recommended dose is one to two drops of Betoptic in the affected eye(s) twice daily. For Betoptic S (suspension), shake well before using. Press the inner corner of the eye for 1-2 minutes after instillation to reduce systemic absorption.
- Body Weight
- Below 5 kg
- Dose
- Not established
- Frequency
- Not recommended
- Tracking Notes
- Safety and effectiveness of ophthalmic beta-blockers in pediatric patients have not been established routinely.
- Body Weight
- 5-7 kg
- Dose
- Not established
- Frequency
- Not recommended
- Tracking Notes
- Safety and effectiveness of ophthalmic beta-blockers in pediatric patients have not been established routinely.
- Body Weight
- 8-10 kg
- Dose
- Not established
- Frequency
- Not recommended
- Tracking Notes
- Safety and effectiveness of ophthalmic beta-blockers in pediatric patients have not been established routinely.
- Body Weight
- 11-15 kg
- Dose
- Not established
- Frequency
- Not recommended
- Tracking Notes
- Safety and effectiveness of ophthalmic beta-blockers in pediatric patients have not been established routinely.
- Body Weight
- 16-20 kg
- Dose
- Not established
- Frequency
- Not recommended
- Tracking Notes
- Safety and effectiveness of ophthalmic beta-blockers in pediatric patients have not been established routinely.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not established | Not recommended | Safety and effectiveness of ophthalmic beta-blockers in pediatric patients have not been established routinely. |
| 5-7 kg | Not established | Not recommended | Safety and effectiveness of ophthalmic beta-blockers in pediatric patients have not been established routinely. |
| 8-10 kg | Not established | Not recommended | Safety and effectiveness of ophthalmic beta-blockers in pediatric patients have not been established routinely. |
| 11-15 kg | Not established | Not recommended | Safety and effectiveness of ophthalmic beta-blockers in pediatric patients have not been established routinely. |
| 16-20 kg | Not established | Not recommended | Safety and effectiveness of ophthalmic beta-blockers in pediatric patients have not been established routinely. |
Formulation
Purpose
Lowering elevated intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension
Generic Name
Betaxolol hydrochlorideScheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.